On this page
Back to topEvommune EVMN
Evommune listed on NYSE on 6 Nov 2025 and is not in the S&P 500. It is worth $299 million. Its price history starts on 7 Nov 2025. Its board has 9 directors, 6 of them independent. 4 other officers are on file. At 30 Jun 2026, Eqt Fund Management S.a r.l. was its largest institutional holder, with 14.7% of the company.
- CEO
- Luis C. Pena
- Chair
- Benjamin F. McGraw, III, Pharma. D.
- Listed
- 6 Nov 2025 on NYSE
- Headquarters
- Palo Alto, CA
- Market cap
- $299M
- 19 Nov 2026 close
- Price to sales
- 23.0
- Market cap over revenue
Financials
Financial history
Twelve months to 30 Sep 2025, from Evommune's quarterly filings.
Quarters since Mar 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Mar 2025 to Sep 2025
Not reported for enough quarters.
Not reported for enough quarters.
Not reported for enough quarters.
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2025 | $10M | $-12M |
| Mar 2025 | $3M | $-15M |
Evommune's market cap since November 2025
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $320M |
| 26 Dec 2025 | $540M |
Download Evommune's data as JSON, with the weekly market caps in billions of dollars from 7 Nov 2025.
Board and leadership
Board and officers
Board from the proxy filed 21 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (9) | |||||
| Benjamin F. McGraw, III, Pharma. D.ChairIndependent 路 since 2020 路 Audit, Compensation (chair), Nominating and Corporate Governance, Science and TechnologyExecutive Chairman, Perfuse TherapeuticsOther boards: Aerie Pharmaceuticals | |||||
| Luis C. PenaPresident & CEONot independent 路 since 2020 路 Nominating and Corporate Governance | |||||
| Eugene BauerChief Medical OfficerNot independent 路 since 2020 路 Science and Technology | |||||
| David E. CohenDirectorIndependent 路 since 2020 路 Compensation, Nominating and Corporate Governance (chair), Science and Technology (chair)Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis and Director of Occupational and Environmental Dermatology, New York University School of Medicine | |||||
| Derek DiRocco, Ph.D.DirectorIndependent 路 since 2024 路 Audit, Science and TechnologyPartner, RA Capital ManagementOther boards: 89Bio, Mineralys, Werewolf Therapeutics and Acrivon Therapeutics | |||||
| Arthur S. KirschDirectorIndependent 路 since 2025 路 Audit (chair), CompensationConsultant, Alvarez & MarsalOther boards: Liquidia Corporation and Atea Pharmaceuticals | |||||
| Benjamin F. McGraw IIIDirector | |||||
| Rob Hopfner, R.Ph., Ph.D.DirectorIndependent 路 since 2020 路 Audit, Science and TechnologyManaging Partner, Pivotal bioVenture Partners | |||||
| Felice Isabel Verduyn-van WeegenDirectorIndependent 路 since 2021 路 Nominating and Corporate Governance, Science and TechnologyPartner, EQT | |||||
| Officers (4) | |||||
| Kyle CarverChief Financial OfficerLast filed 10 Jul 2026 | |||||
| Janice Suzann DrewChief of Dev. OperationsLast filed 24 Jun 2026 | |||||
| Gregory S. MossChief Business & Legal OfficerLast filed 1 Jun 2026 | |||||
| Jeegar Pravinkumar PatelChief Scientific OfficerLast filed 24 Jun 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Evommune. Where a company has several share classes, the share is of its total value. Stakes are of the shares out at 30 Jun 2026; the count has since grown 15%.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $2.3 million of stock in 8 sales and bought $163,610 in 3 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 8 Jul 2026Buy | Kyle CarverChief Financial Officer | $13K |
| 7 Jul 2026Buy | Arthur S. KirschDirector | $133K |
| 22 Jun 2026Sale | Janice Suzann DrewChief of Dev. Operations | $453K |
| 22 Jun 2026Sale | Luis C. PenaPresident & CEO | $169K |
| 22 Jun 2026Sale | Jeegar Pravinkumar PatelChief Scientific Officer | $33K |
| 2 Jun 2026Sale | David E. CohenDirector | $123K |
| 1 Jun 2026Sale | Luis C. PenaPresident & CEO | $382K |
| 1 Jun 2026Sale | Jeegar Pravinkumar PatelChief Scientific Officer | $379K |
| 28 May 2026Sale | Kyle CarverChief Financial Officer | $415K |
| 28 May 2026Sale | Gregory S. MossChief Business & Legal Officer | $325K |
Showing 10 of 11 trades
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Evommune's insider sales.
Events, newest first
- 22 Jun 2026 Janice Suzann Drew sold $453KChief of Dev. Operations
| Date | Event | Filing |
|---|---|---|
| 22 Jun 2026 | Janice Suzann Drew sold $453KChief of Dev. Operations | Form 4 |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.